Making the CASE: Chemopreventive use of Aspirin for Ovarian Cancer- Integrating Epidemiological Data to Evaluate Population Subgroups and Tumor Expression
Abstract
We hypothesize that the use of updated exposure information in cohort analyses will clarify and refine the ovarian cancer risk reductionassociated with aspirin, that there are subgroups of women who will derive the most benefit from daily aspirin use with respect to ovarian cancerchemoprevention, and that aspirin will preferentially reduce risk for ovarian cancers dependent on the tumor immune microenvironment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1166361
Entities
People
- Britton Trabert
Organizations
- Geneva Foundation